{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-033367","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.943655+00:00","generated_at":"2026-06-18T00:10:44.505110+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Onconova full-year net loss $19.0M; cash $38.8M into Q1 2024","bullets":["Net loss $19.0M ($0.91 loss per share) vs $16.2M ($0.96 loss per share) in 2021 on higher shares outstanding.","Cash and equivalents $38.8M at Dec 31, 2022, down from $55.1M; cash runway into Q1 2024.","R&D expenses rose to $11.4M from $7.3M, driven by narazaciclib development and manufacturing.","Narazaciclib Phase 1 advancing to 240 mg continuous daily cohort; LGEEC trial opening Q1 2023, data Q4 2023.","Two complete responses in RDEB-associated SCC with rigosertib; plan to discuss regulatory path with agencies."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-033367","json":"https://secwatch.observer/filing/0001104659-23-033367.json","markdown":"https://secwatch.observer/filing/0001104659-23-033367.md","text":"https://secwatch.observer/filing/0001104659-23-033367.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465923033367/0001104659-23-033367-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465923033367/tm239793d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:10:44.505110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ba77e68170dfc1f428c952fe5700aceda7e6beac","claim":"Traws Pharma, Inc. reported the twelve months ended December 31, 2022 results: net income $19.0 million, EPS $0.91 per share.","evidence_excerpt":"Net loss for 2022 was $19.0 million, or $0.91 per share on 20.9 million weighted average shares outstanding, compared with a net loss of $16.2 million, or $0.96 per share for 2021 based on 16.8 million weighted average shares outstanding.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465923033367/0001104659-23-033367-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the twelve months ended December 31, 2022"},{"label":"Net income","value":"$19.0 million"},{"label":"EPS","value":"$0.91 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}